<DOC>
	<DOCNO>NCT01455194</DOCNO>
	<brief_summary>The aim trial investigate asthma control 160 640 mcg ciclesonide/day . Asthma control assess Asthma Control Questionnaire ( ACQ ) .</brief_summary>
	<brief_title>Effect High Dose Ciclesonide Asthma Control</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Written inform consent provide History persistent bronchial asthma least 6 month Current treatment Inhaled Corticosteroid ( ICS ) stable dose dose range 2001000 μg Fluticasone Propionate ( FP ) /day equivalent minimum 12 week Good inhalation technique Under current ICS pretreatment ACQ score range ≥ 0.75 ≥ 2 Clinically relevant abnormal laboratory value suggest unknown disease require clinical evaluation Concomitant severe disease ( e.g . malignant disease past 5 year [ basal squamous cell carcinoma ] , hepatitis C , acquire immune deficiency syndrome [ AIDS ] ) Diseases contraindication use ICS ( e.g . active inactive pulmonary tuberculosis relevant fungal , bacterial viral infection low respiratory tract demand specific treatment ) Use systemic glucocorticosteroids within 4 week ( injectable depot steroid 6 week ) entry baseline period , 3 time last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ciclesonide</keyword>
	<keyword>asthma</keyword>
</DOC>